NeOnc Technologies Holdings Inc. Common Stock (NTHI)

About NTHI

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

5

Website

neonc.com

Fundamentals

1-day range

$4.51$4.74

Market cap

$89.73M

P/E (trailing)

—

P/E (forward)

-4.66

EPS (trailing)

$-1.86

Dividend yield

—

Beta

2.73

Avg. volume

150.7K

Forecasts

3 analyst ratings

NeOnc Technologies Holdings Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• NTHI

  NeOnc Technologies Holdings Inc. Common Stock

  $4.69

  ▲ 1.74%
  Market cap $89.73MP/E —
  $3.01$12.99
• VRCA

  Verrica Pharmaceuticals Inc. Common Stock

  $5.54

  ▲ 9.27%
  Market cap $90.19MP/E —
  $3.28$9.82
• FBIO

  Fortress Biotech Inc. Common Stock

  $2.77

  ▼ 1.07%
  Market cap $91.68MP/E 0.75
  $2.18$4.53
• ALDX

  Aldeyra Therapeutics Inc. Common Stock

  $1.49

  ▼ 3.57%
  Market cap $92.29MP/E —
  $1.07$6.18
• ONCY

  Oncolytics Biotech Inc. Common Stock

  $0.8457

  ▼ 0.51%
  Market cap $92.50MP/E —
  $1.39$1.44
• ACET

  Adicet Bio Inc. Common Stock

  $9.05

  ▲ 0.44%
  Market cap $86.38MP/E —
  $6.01$17.44
• LFVN

  Lifevantage Corporation Common Stock (Delaware)

  $6.6

  ▲ 2.33%
  Market cap $83.01MP/E 14.23
  $3.9$14.28

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• 12 Health Care Stocks Moving In Friday's Intraday Session
  Benzinga · 8/14/2026
• Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26
  Yahoo · 8/13/2026
• NeOnc Technologies shares jump after positive Phase 2a glioma results
  Yahoo · 8/12/2026
• NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x
  Yahoo · 8/12/2026
• 12 Health Care Stocks Moving In Wednesday's Intraday Session
  Benzinga · 8/12/2026
• NeOnc Technologies Reports Positive Topline Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma
  Yahoo · 8/12/2026
• NeOnc Technologies Announces Topline Results From Its Phase 2A Portion Of NEO100-01 Study Of Intranasal NEO100 In Patients With Recurrent Or Progressive Glioma; Study Met Its Primary Endpoint; Will Request Type B Meeting With FDA
  Benzinga · 8/12/2026
• NTHI Brain Cancer Phase 2 Data Expected to Spark Triple Confluence
  Yahoo · 8/11/2026

• Nasim Shomali · July 10, 2026 · Grant

  50.0K
• Amir F. Heshmatpour · May 1, 2026 · Buy

  10.0K @ $4.16
• Amir F. Heshmatpour · April 28, 2026 · Buy

  10.0K @ $4.52
• Yousha Neman-Ebrahim · April 23, 2026 · Buy

  500 @ $4.88
• Amir F. Heshmatpour · April 23, 2026 · Buy

  10.0K @ $4.9
• Amir F. Heshmatpour · April 10, 2026 · Buy

  10.0K @ $4.9
• SUH, DAVID JR. · April 9, 2026 · Buy

  200 @ $5
• Amir F. Heshmatpour · April 9, 2026 · Buy

  5.0K @ $5.19
• Amir F. Heshmatpour · April 8, 2026 · Buy

  10.0K @ $5.61
• Amir F. Heshmatpour · April 6, 2026 · Buy

  5.0K @ $6.32
• Amir F. Heshmatpour · April 2, 2026 · Buy

  20.0K @ $6.09
• SUH, DAVID JR. · March 1, 2026 · Grant

  58.3K
• SUH, DAVID JR. · March 1, 2026 · Grant

  111.7K

Institutional Ownership

March 31, 2026

Total shares held

2.84M

Total value held

$19.74M

Institutional holders

24